Research Use Only. Reference materials for laboratory research — not for human or veterinary use.
Home / Learn / CJC-1295 / Ipamorelin (no DAC)
Growth-hormone secretagogue research · 4 articles

CJC-1295 / Ipamorelin (no DAC)

CJC-1295 (no DAC) / Ipamorelin blend (GHRH-analog + ghrelin/GHS-R agonist secretagogue pair) · 5 min read

This catalog item is a two-component research blend (catalog strength 20 mg) supplied as a lyophilized powder for Research-Use-Only applications. It pairs CJC-1295 without DAC (Mod GRF 1-29), a tetrasubstituted synthetic analog of growth-hormone-releasing hormone GHRH(1-29), with Ipamorelin, a pentapeptide selective agonist of the growth-hormone-secretagogue (ghrelin) receptor. Because it is a blend, no single CAS, molecular formula, or molecular weight applies; each component is characterized separately by sequence and analytical identity. The material is intended as a characterized reference standard for in-vitro and laboratory investigation only.

Component identity

CJC-1295 without DAC (Mod GRF 1-29) is a 29-residue GHRH(1-29) analog with substitutions at positions 2, 8, 15 and 27 (including D-Ala at position 2) reported in the literature to confer resistance to enzymatic cleavage; molecular formula C152H252N44O42 (~3367.9 g/mol). Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 (C38H49N9O5; ~711.85 g/mol; CAS 170851-70-4; PubChem CID 9831659), incorporating the non-natural residues aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2-Nal).

Mechanism themes in the literature

The two components are described in published work as acting on distinct receptors: the CJC-1295 (no DAC) component is characterized as a GHRH-receptor (GHRH-R) agonist, while the Ipamorelin component is characterized as a selective agonist at the growth-hormone-secretagogue receptor (GHS-R1a / ghrelin receptor). The pairing is of interest as a model for studying two complementary signaling nodes of the somatotrope axis in vitro.

Research context (RUO)

Supplied strictly as a Research-Use-Only reference material for in-vitro and analytical work — for example receptor-pharmacology and GPCR signaling assays, structure-activity studies of peptide secretagogue analogs, and HPLC/MS-based identity and purity characterization. Not for human or veterinary use; not a drug, food, or cosmetic.

Handling and analytical identity

Provided as a lyophilized powder at ≥98% (HPLC) purity. As a multi-component blend it carries no single CAS, molecular formula, or molecular weight; identity is established per component by amino-acid sequence and orthogonal HPLC / mass-spectrometric characterization.

Documented in every box

Every CJC-1295 / Ipamorelin (no DAC) order includes a sealed, lot-controlled vial, the completed lot documentation, and a handling & storage card. Product-specific handling follows the supplied documentation and institutional SOPs.

Evidence limits and research safety

Research findings can differ by model, assay, purity, formulation, and study design. Published cell, biochemical, and pre-clinical observations do not establish human or veterinary safety, efficacy, dosing, or suitability. Researchers should review the applicable SDS, institutional safety procedures, waste requirements, and lot-specific documentation before handling any reference material.

Related research

Tesamorelin

Credible sources

Research context only. This article summarizes published in-vitro and pre-clinical research for scientific context. It is not a claim of efficacy or safety and does not constitute medical, usage, or dosing guidance. HELIX BioScience products are Research Use Only and not for human or veterinary use.

More on CJC-1295 / Ipamorelin (no DAC)

Methods note

CJC-1295 / Ipamorelin: mixed-analyte method planning

CJC-1295 / Ipamorelin: mixed-analyte method planning explains how a laboratory team can frame CJC-1295 / Ipamorelin (no DAC) as a characterized research reference for planning an analytical method for a two-component reference rather than treating the blend as one analyte. The emphasis is on reproducible preparation, analytical controls, and careful interpretation—not on therapeutic, diagnostic, or in-vivo use.

7 min read
Methods note

CJC-1295 / Ipamorelin: reference-material acceptance

CJC-1295 / Ipamorelin: reference-material acceptance explains how a laboratory team can frame CJC-1295 / Ipamorelin (no DAC) as a characterized research reference for deciding what evidence is sufficient before a two-component reference enters a study. The emphasis is on reproducible preparation, analytical controls, and careful interpretation—not on therapeutic, diagnostic, or in-vivo use.

7 min read
Methods note

CJC-1295 / Ipamorelin: lot traceability

CJC-1295 / Ipamorelin: lot traceability explains how a laboratory team can frame CJC-1295 / Ipamorelin (no DAC) as a characterized research reference for keeping each component and preparation event traceable in a two-component reference study. The emphasis is on reproducible preparation, analytical controls, and careful interpretation—not on therapeutic, diagnostic, or in-vivo use.

7 min read